CRISPR Therapeutics AG (CRSP) Rises But Trails Market: Investors Should Know

Last trading day, CRISPR Therapeutics AG (CRSP) finished at $64.75, up 0.12%. The stock behind the S&P 500's 1.07% daily gain. Meanwhile, the Dow rose 0.35% and the tech-heavy Nasdaq rose 1.74%.

Over the past month, the company's shares have gained 4.41%, outperforming the Medical sector's 4.02% and the S&P 500's 2.93%.

CRISPR Therapeutics AG's forthcoming earnings report will be closely watched by investors. The company's EPS is expected to be -$0.21, up 85.11% from previous quarter. Sales are expected to reach $144.28 million, up 1442670% from the previous year, according to the Zacks Consensus Estimate.

Investors should also monitor CRISPR Therapeutics AG analyst estimate changes. Recent changes frequently reflect short-term business practices. Thus, positive estimate changes indicate analyst confidence about the company's operations and profitability.

Our study reveals that estimate changes affect stock price performance. Investors might benefit from Zacks Rank. This model incorporates estimate changes and provides a simple, actionable scoring system.

External audits show that stocks at #1 have delivered an average yearly return of +25% since 1988, proving the Zacks Rank system's success. The Zacks Consensus EPS forecast dropped 7.78% in 30 days. CRISPR Therapeutics AG rated #3 (Hold) on Zacks.

The Medical sector includes Biomedical and Genetics. The Zacks Industry Rank of 96 places this industry in the top 39% of all industries, with over 250.

Using the average Zacks Rank of the companies in our industry categories, the Zacks Industry Rank measures their strength. Our analysis reveals that the top 50% of ranked sectors outperform the bottom half 2 to 1.